Handelsbanken Fonder’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-45,900
| Closed | -$233K | – | 1529 |
|
|
2024
Q1 | $233K | Hold |
45,900
| – | – | ﹤0.01% | 1461 |
|
|
2023
Q4 | $275K | Buy |
45,900
+10,400
| +29% | +$62.3K | ﹤0.01% | 1407 |
|
|
2023
Q3 | $251K | Hold |
35,500
| – | – | ﹤0.01% | 1374 |
|
|
2023
Q2 | $250K | Hold |
35,500
| – | – | ﹤0.01% | 1416 |
|
|
2023
Q1 | $296K | Hold |
35,500
| – | – | ﹤0.01% | 1295 |
|
|
2022
Q4 | $408K | Buy |
35,500
+8,400
| +31% | +$96.5K | ﹤0.01% | 1067 |
|
|
2022
Q3 | $341K | Sell |
27,100
-8,600
| -24% | -$108K | ﹤0.01% | 1172 |
|
|
2022
Q2 | $378K | Hold |
35,700
| – | – | ﹤0.01% | 1186 |
|
|
2022
Q1 | $580K | Sell |
35,700
-11,400
| -24% | -$185K | ﹤0.01% | 1092 |
|
|
2021
Q4 | $652K | Sell |
47,100
-18,600
| -28% | -$257K | ﹤0.01% | 1166 |
|
|
2021
Q3 | $944K | Buy |
65,700
+6,200
| +10% | +$89.1K | ﹤0.01% | 937 |
|
|
2021
Q2 | $941K | Buy |
+59,500
| New | +$941K | ﹤0.01% | 959 |
|